Business Wire

Prosimo Announces General Availability of AWS Cloud WAN Integration

12.7.2022 20:52:00 EEST | Business Wire | Press release

Share

Prosimo, the Application Experience Infrastructure company, today announced the general availability of its integration with AWS Cloud WAN. This comes on the heels of AWS announcing today the general availability of AWS Cloud WAN. AWS Cloud WAN customers can now deploy the Prosimo platform to build an elastic and scalable Full Stack Cloud Transit for cross-region connectivity and segmentation to simplify and reduce operational burdens, deliver better experiences and lower costs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712005998/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

AWS Cloud WAN customers can now deploy the Prosimo platform to build an elastic and scalable Full Stack Cloud Transit for cross-region connectivity and segmentation to simplify and reduce operational burdens, deliver better experiences and lower costs. (Graphic: Business Wire)

"With these new features and functionality on the AXI Platform, Prosimo will be ideally suited to meet our goals: enable modern infrastructure capabilities using newer AWS networking constructs such as Cloud WAN, built-in observability for applications, and remove as much complexity as possible,” said Kevin Paige, CISO, Flexport

Enterprises can now simplify how they build and manage connectivity of their disparate environments across AWS regions across the globe, on-premises data centers, colocation facilities, branch offices, and their distributed user base with the combination of AWS Cloud WAN and Prosimo:

  • Achieve fine-grained elastic segmentation – The global network policy in AWS is kept coarse-grained and straightforward by design to be easy to manage and does not change that frequently. Fine-grained policy-based segmentation and security is the requirement from the application teams, in addition to the network layer segmentation. Prosimo helps to build policies at the per user and per-application level, on top of global network segments from Cloud WAN.
  • Hassle-free connectivity from AWS to any cloud – Regardless of how customers approach the core network policy, they will seek to achieve similar hassle-free connectivity to any of their DCs, other cloud providers, and edge co-locations. Prosimo helps extend the same core network policy model with segmentation to any cloud, including on-prem locations.
  • Modern cloud / NetDevOps operational model – Internal constituents such as modern cloud or NetDevOps teams will achieve a higher change frequency. With Prosimo’s APIs and Terraform modules, enterprise teams can integrate with their CI/CD flows for more agile development and deployment models while adhering to security and compliance guardrails and maintaining operational consistency.

Related Link: Sign up directly from the AWS Marketplace .

AWS Cloud WAN furthers Autonomous Multi-cloud Networking Solution

To ensure their multi-cloud environment is consistent, and easy-to-use, enterprises need to build an intelligent fabric that automatically connects applications, services, and networks across cloud infrastructures based on pre-set operations, security, and performance requirements. This requires first solving cloud connectivity issues then building an app transit layer that is autonomous and machine-driven to mitigate inherent complexity. Combining Network Transit and App Transit in a single architecture that simplifies and, most importantly, automates multi-cloud networking.

One Platform to Rule Them All

The combined network transit and app-to-app transit create a Full Stack Cloud Transit built on cloud-native constructs to take advantage of AWS’s global presence including AWS Cloud WAN. This gives enterprises a simpler connectivity model to migrate and connect their brownfield cloud deployments to deliver consistent, reliable, and secure Zero Trust-driven networks to support business-critical and latency-sensitive applications for users in any location.

“Our deepening relationship with AWS reflects the growing interest from AWS customers for simplified cloud networking solutions beyond just connectivity,” said Mani Ganesan, Head of Products, Prosimo. “AWS Cloud WAN and Prosimo offer a seamless and tightly integrated autonomous cloud networking solution as enterprises continue their enterprise cloud journeys and modernize their infrastructure.”

Resources

Connect with Prosimo

About Prosimo:

Prosimo delivers simplified multi-cloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have adopted Prosimo to successfully roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst and WRVI Capital. For more information, visit https://www.prosimo.io.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press and Analyst Contact:
Matt Stubbs
Outside Labs for Prosimo
(801) 703-6626
press@prosimo.io

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye